New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine ...Middle East

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant reductions compared to placebo in mean monthly migraine days (MMDs) within the first 4 weeks, in...

Hence then, the article about new data demonstrates robust efficacy of vyepti eptinezumab in otherwise difficult to treat patients with severe migraine was published today ( Saturday 21/06/2025 - 03:57 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine )

Also on site :

• Iranian Foreign Minister spokesperson in exclusive interview discusses cause of the war and Iran’s stance
• Walmart’s 'Very Sturdy' $53 3-Piece Patio Set Is Perfect for Small-Space Entertaining
• AI success is a leadership test—and the 100 Best Companies lead the way